US Patent Issued to Amal Therapeutics on Oct. 28 for "Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for treatment of glioblastoma" (Swiss Inventors)

ALEXANDRIA, Va., Oct. 28 -- United States Patent no. 12,453,762, issued on Oct. 28, was assigned to Amal Therapeutics SA (Geneva).

"Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for treatment of glioblastoma" was invented by Madiha Derouazi (Grand-Saconnex, Switzerland) and Elodie Belnoue (Geneva).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides a novel complex for use in the prevention and/or treatment of glioma, in particular glioblastoma, the complex comprising a) a cell penetrating peptide, b) at least one antigen or antigenic epitope, and c) at least one TLR peptide agonist, wherein the components a)-c) are covalently linked. In particular, ...